Mr. Thomas Alston Lyons, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: West Pavillon 2nd Floor 130 2nd Street, The Neuroscience Group Of Ne Wi, Neenah, WI 54956 Phone: 920-725-9373 Fax: 920-720-7392 |
Mr. Randall Roy Johnson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1305 W American Dr, Neenah, WI 54956 Phone: 920-725-9373 Fax: 920-720-7392 |
Mr. Philip Andrew Yazbak, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1305 W American Dr, Neenah, WI 54956 Phone: 920-725-9373 Fax: 920-720-7392 |
Mr. Alexander Todd Hawkins, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1305 W American Dr, Neenah, WI 54956 Phone: 800-201-1194 Fax: 920-720-7392 |
Mr. Sumon Bhattacharjee, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1305 W American Dr, Neenah, WI 54956 Phone: 920-725-9373 Fax: 920-720-7392 |
Evan Krueger, Neurological Surgery Medicare: Medicare Enrolled Practice Location: 1305 W American Dr, Neenah, WI 54956 Phone: 920-729-7687 |
News Archive
A group including scientists from the Florida campus of The Scripps Research Institute (TSRI) has been awarded a grant from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health to study the role of microRNAs in a range of physiological activities, including memory, sleep, synapse function and movement.
According to a new report more Australian privately insured patients used the public hospital system last year than previously and there are concerns that encouraging people to take out private health insurance is doing little to reduce the burden on the public health system.
Rehabilitation clinicians and other health care professionals now have a framework for assessing and managing people who may have serious spinal pathologies.
A new study by researchers at The Hebrew University of Jerusalem in Israel reports the discovery of a promising group of E channel inhibitors with significant antiviral activity. This could be developed into new treatment agents for this often-deadly virus.
A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.
› Verified 3 days ago